C&EN Senior Editor Celia Henry Arnaud notes that collecting drops of blood from patients and depositing the drops on special paper cards to dry has been used for decades to screen newborns for hereditary disorders and infectious disease. But the dried blood spot technology has found a new role at pharmaceutical companies in the development and testing of new drugs.
The approach, possible now because modern lab instruments are more sensitive, has distinct advantages. The dried blood approach, for instance, involves taking only a few drops of blood from patients in clinical trials, and these can be stored and shipped more easily and inexpensively than liquid samples. Those advantages, alone, could cut the cost of introducing new drugs by millions of dollars, the article indicates.ARTICLE FOR IMMEDIATE RELEASE
Michael Bernstein | EurekAlert!
Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden
The pyrenoid is a carbon-fixing liquid droplet
22.09.2017 | Max-Planck-Institut für Biochemie
A warming planet
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy